search

Active clinical trials for "Kidney Neoplasms"

Results 1-10 of 809

Tislelizumab Plus Lenvatinib in Stage III-IV RCC

Advanced Kidney Cancer

This is a phase II study to determine the efficacy and safety of Tislelizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer . Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects

Recruiting23 enrollment criteria

HTL0039732 in Participants With Advanced Solid Tumours

NeoplasmsProstatic Neoplasms14 more

The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.

Recruiting47 enrollment criteria

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors...

SarcomaCarcinoma8 more

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

Recruiting23 enrollment criteria

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Atypical Teratoid Rhabdoid TumorINI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors5 more

This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4. The names of the study drugs involved in this study are: Tazemetostat (TAZVERIK) Nivolumab (OPDIVO) Ipilimumab (YERVOY)

Recruiting74 enrollment criteria

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With...

Solid TumorAdult19 more

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

Recruiting17 enrollment criteria

NSAID Use After Robotic Partial Nephrectomy

Kidney CancerRenal Cancer1 more

The purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.

Recruiting12 enrollment criteria

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

Renal Cancer Metastatic

The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).

Recruiting13 enrollment criteria

Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer

Triple Negative Breast CancerRenal Cell Cancer2 more

The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1/Modi-1v vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab (where these are standard of care in a non-neoadjuvant setting), in patients with advanced triple negative breast cancer (TNBC), advanced/unresectable human papillomavirus-negative squamous cell carcinoma of the head and neck (SCCHN), high grade serous ovarian carcinoma (HGSOC), or renal cell carcinoma (RCC). Modi-1 will also be investigated in the neoadjuvant setting for patients with SCCHN undergoing curative intent surgical resection in combination with pembrolizumab versus the Modi-1 alone.

Recruiting62 enrollment criteria

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors...

Metastatic CancerMelanoma Cancer4 more

Drugs called checkpoint inhibitors help the immune system fight cancer. When the effectiveness of these drugs wears off, it may be possible to renew their effectiveness by combining it with a special type of radiation therapy called stereotactic body radiation therapy (SBRT). SBRT is a commonly used type of radiation therapy that gives high dose radiation with high precision to tumors in 1-5 treatments. Radiation therapy, such as SBRT can also treat sites of metastases. The use of checkpoint inhibitors in combination with SBRT has been suggested to improve the immune response against cancer but has not been tested in a formal clinical trial. Up to three lesions can be treated with SBRT. This study only allows checkpoint inhibitors that are already approved by the Federal Drug Agency (FDA) for the treatment of your disease. All radiation therapy will be done on machines which are FDA approved.

Recruiting27 enrollment criteria

9-ING-41 in Patients With Advanced Cancers

CancerPancreatic Cancer24 more

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

Recruiting69 enrollment criteria
12...81

Need Help? Contact our team!


We'll reach out to this number within 24 hrs